4.6 Article

Treatment Considerations for Elderly and Frail Patients With Neuropathic Pain

期刊

MAYO CLINIC PROCEEDINGS
卷 85, 期 3, 页码 S26-S32

出版社

ELSEVIER SCIENCE INC
DOI: 10.4065/mcp.2009.0646

关键词

-

资金

  1. Merck
  2. Wyeth
  3. Pfizer Pharma
  4. Genzyme
  5. Grunenthal
  6. Johnson Johnson
  7. Spinifex
  8. AstraZeneca

向作者/读者索取更多资源

Currently, an estimated 38 million Individuals 65 years or older live in the United States, and more than 11 million of these individuals are 80 years or older. Older people are at high risk of neuropathic pain because many diseases that cause neuropathic pain increase in incidence with age. Depending on their underlying health, older adults with neuropathic pain may have to cope with multiple coexisting diseases, polypharmacy, and Impaired functional ability. The objective of this article Is to review how aging and frailty affect the treatment of older adults with neuropathic pain. Specific topics reviewed include the complexity of treatment decisions In older patients due to aged heterogeneity, multimorbidity, and polypharmacy; selection of treatment in an effort to maximize patients' functional abilities In addition to relieving their pain; more careful dosing (usually lower) and monitoring of pharmacotherapy relative to younger patients due to age-related changes in pharmacokinetics and pharmacodynamics; and underrepresentation of older adults In clinical trials of neuropathic pain treatments, which further compromises physicians' ability to make informed treatment decisions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据